Prometheus Biosciences, Inc. – NASDAQ:RXDX
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 1 hour
Prometheus Biosciences stock price monthly change
+2.20%
month
Prometheus Biosciences stock price quarterly change
+69.60%
quarter
Prometheus Biosciences stock price yearly change
+603.26%
year
Prometheus Biosciences key metrics
Market Cap | 9.55B |
Enterprise value | 4.36B |
P/E | -31.66 |
EV/Sales | 641.25 |
EV/EBITDA | -30.87 |
Price/Sales | 679.86 |
Price/Book | 6.84 |
PEG ratio | 0.62 |
EPS | -3.34 |
Revenue | 7.33M |
EBITDA | -145.80M |
Income | -137.85M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -2081.83% |
Oper. margin | -2140.96% |
Gross margin | 18.64% |
EBIT margin | -2140.96% |
EBITDA margin | -1989.21% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freePrometheus Biosciences stock price history
Prometheus Biosciences stock forecast
Prometheus Biosciences financial statements
| Dec 2021 | 1.03M | -31.61M | -3048.6% |
|---|---|---|---|
| Mar 2022 | 3.91M | -32.03M | -817.45% |
| Jun 2022 | 1.26M | -33.32M | -2626.16% |
| Mar 2023 | 1.10M | -40.87M | -3699.19% |
| 2022-11-09 | -0.9 | -0.9 |
|---|---|---|
| 2023-02-28 | -0.87939 | -0.9 |
| Jun 2022 | 237589000 | 45.75M | 19.26% |
|---|---|---|---|
| Sep 2022 | 298618000 | 66.08M | 22.13% |
| Dec 2022 | 740773000 | 64.80M | 8.75% |
| Mar 2023 | 758414000 | 60.79M | 8.02% |
| Dec 2021 | -22.17M | -190K | 505K |
|---|---|---|---|
| Mar 2022 | -29.38M | -955K | 123K |
| Jun 2022 | -28.84M | -116.86M | 14.63M |
| Mar 2023 | -39.54M | -192.33M | 52.79M |
Prometheus Biosciences alternative data
| Aug 2023 | 97 |
|---|---|
| Sep 2023 | 97 |
| Oct 2023 | 97 |
| Nov 2023 | 97 |
| Dec 2023 | 97 |
| Jan 2024 | 97 |
| Feb 2024 | 97 |
| Mar 2024 | 97 |
| Apr 2024 | 97 |
| May 2024 | 97 |
| Jun 2024 | 97 |
| Jul 2024 | 97 |
Prometheus Biosciences other data
38.29%
-54.02%
of RXDX is owned by hedge funds
128
-91
15.55M
-22.49M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2023 | 0 | 30000 |
| Feb 2023 | 0 | 68680 |
| Mar 2023 | 0 | 911320 |
| Apr 2023 | 0 | 10000 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | MCKENNA MARK C. director, officer.. | Common Stock | 122,528 | $2.9 | $355,331 | ||
Option | MCKENNA MARK C. director, officer.. | Common Stock | 122,528 | $2.9 | $355,331 | ||
Option | MCKENNA MARK C. director, officer.. | Common Stock | 3 | $1.7 | $5 | ||
Option | MCKENNA MARK C. director, officer.. | Common Stock | 3 | $1.7 | $5 | ||
Option | MCKENNA MARK C. director, officer.. | Stock Option (Right to Buy) | 122,528 | $2.9 | $355,331 | ||
Option | MCKENNA MARK C. director, officer.. | Stock Option (Right to Buy) | 122,528 | $2.9 | $355,331 | ||
Option | MCKENNA MARK C. director, officer.. | Stock Option (Right to Buy) | 3 | $1.7 | $5 | ||
Option | MCKENNA MARK C. director, officer.. | Stock Option (Right to Buy) | 3 | $1.7 | $5 | ||
Option | MARSHALL KEITH W officer: Chief Fi.. | Common Stock | 78,162 | $3.1 | $242,302 | ||
Option | MARSHALL KEITH W officer: Chief Fi.. | Common Stock | 78,162 | $3.1 | $242,302 |
| Patent |
|---|
Grant Filling date: 2 Dec 2020 Issue date: 5 Apr 2022 |
Application Filling date: 18 May 2021 Issue date: 9 Dec 2021 |
Grant Utility: Methods of treating Crohn's disease or ulcerative colitis by administering inhibitors of tumor necrosis factor-like cytokine 1A (TL1A) Filling date: 10 Dec 2020 Issue date: 5 Oct 2021 |
Application Filling date: 26 Apr 2019 Issue date: 5 Aug 2021 |
Grant Utility: GPR35 modulators Filling date: 23 Jan 2020 Issue date: 6 Jul 2021 |
Application Filling date: 2 Dec 2020 Issue date: 29 Apr 2021 |
Application Filling date: 10 Dec 2020 Issue date: 8 Apr 2021 |
Application Filling date: 24 Apr 2019 Issue date: 11 Mar 2021 |
Application Filling date: 13 May 2020 Issue date: 19 Nov 2020 |
Grant Filling date: 1 Sep 2016 Issue date: 6 Oct 2020 |
| Insider | Compensation |
|---|---|
| Mr. Mark C. McKenna (1980) Pres, Chief Executive Officer & Chairman | $1,510,000 |
| Dr. Allison Luo M.D. (1973) Chief Medical Officer | $586,130 |
Dr. Keith W. Marshall M.B.A., MBA, Ph.D. (1968) Chief Financial Officer & Treasurer | $458,220 |
-
When is Prometheus Biosciences's next earnings date?
Unfortunately, Prometheus Biosciences's (RXDX) next earnings date is currently unknown.
-
Does Prometheus Biosciences pay dividends?
No, Prometheus Biosciences does not pay dividends.
-
How much money does Prometheus Biosciences make?
Prometheus Biosciences has a market capitalization of 9.55B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 509.03% to 6.81M US dollars. Prometheus Biosciences made a loss 141.75M US dollars in net income (profit) last year or -$0.9 on an earnings per share basis.
-
What is Prometheus Biosciences's stock symbol?
Prometheus Biosciences, Inc. is traded on the NASDAQ under the ticker symbol "RXDX".
-
What is Prometheus Biosciences's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Prometheus Biosciences?
Shares of Prometheus Biosciences can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Prometheus Biosciences's key executives?
Prometheus Biosciences's management team includes the following people:
- Mr. Mark C. McKenna Pres, Chief Executive Officer & Chairman(age: 45, pay: $1,510,000)
- Dr. Allison Luo M.D. Chief Medical Officer(age: 52, pay: $586,130)
- Dr. Keith W. Marshall M.B.A., MBA, Ph.D. Chief Financial Officer & Treasurer(age: 57, pay: $458,220)
-
How many employees does Prometheus Biosciences have?
As Jul 2024, Prometheus Biosciences employs 97 workers.
-
When Prometheus Biosciences went public?
Prometheus Biosciences, Inc. is publicly traded company for more then 4 years since IPO on 12 Mar 2021.
-
What is Prometheus Biosciences's official website?
The official website for Prometheus Biosciences is prometheusbiosciences.com.
-
Where are Prometheus Biosciences's headquarters?
Prometheus Biosciences is headquartered at 9410 Carroll Park Drive, San Diego, CA.
-
How can i contact Prometheus Biosciences?
Prometheus Biosciences's mailing address is 9410 Carroll Park Drive, San Diego, CA and company can be reached via phone at 858 684 1300.
Prometheus Biosciences company profile:
Prometheus Biosciences, Inc.
prometheusbiosciences.comExchange:
NASDAQ
Full time employees:
97
Industry:
Biotechnology
Sector:
Healthcare
Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial for the treatment of ulcerative colitis and Crohn's disease, as well as systemic sclerosis-associated interstitial lung disease. The company also develops PR600, an anti-tumor necrosis factor mAb for IBD; PR300, a G-protein coupled receptor modulator small molecule for IBD; PR1100, an anti-cytokine receptor mAb for IBD and other immune-mediated diseases; PR1800, an anti-chemokine mAb for IBD; and PR2100, an anti-inflammatory cytokine mAb for IBD. It has a diagnostics development and collaboration agreement with Takeda Pharmaceutical Company Limited; co-development and manufacturing agreement with Dr. Falk Pharma GmbH; license agreement with Cedars-Sinai Medical Center; and strategic collaboration with Millennium Pharmaceuticals, Inc. The company was formerly known as Precision IBD, Inc. and changed its name to Prometheus Biosciences, Inc. in October 2019. Prometheus Biosciences, Inc. was incorporated in 2016 and is headquartered in San Diego, California.
9410 Carroll Park Drive
San Diego, CA 92121
San Diego, CA 92121
CIK: 0001718852
ISIN: US74349U1088
CUSIP: 74349U108
